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Phase II Study of Pemetrexed and Cisplatin, with Chest
Radiotherapy Followed by Docetaxel in Patients with
Stage III Non-small Cell Lung Cancer
Shirish M. Gadgeel, MD,* John C. Ruckdeschel, MD,* Bhaumik B. Patel, MD,†
Antoinette Wozniak, MD,* Andre Konski, MD,* Manuel Valdivieso, MD,* Deborah Hackstock, BS,*
Wei Chen, PhD,* Kimberly Belzer, MS,* Angelika M. Burger, PhD,‡ Lauren Marquette, BS,‡
and Andrew Turrisi, MD*
Background: Pemetrexed has emerged as one of the most active
agents for the treatment of patients with advanced non-small cell
lung cancer (NSCLC). We conducted a phase II study to assess the
efficacy and feasibility of integrating pemetrexed in a concurrent
therapy plan for patients with stage III NSCLC.
Methods: Patients with stage III NSCLC with performance status 0
to 1, adequate organ function including pulmonary function, and
V20 less than 40% were eligible. Patients were treated with cisplatin
75 mg/m2 (first five patients 60 mg/m2) and pemetrexed 500 mg/m2
every 21 days for three cycles with chest radiotherapy to 66 Gy.
Patients then received three cycles of docetaxel 75 mg/m2 every 21
days. Tumors were analyzed for Excision Repair Cross Complemen-
tation Group 1 and thymidylate synthase.
Results: Patient characteristics (N  28) were median age, 60;
males, 68%; stage IIIB, 64%; and squamous cell, 43%. Twenty-four
patients (86%) completed all three cycles of cisplatin/pemetrexed.
Of the 24 patients eligible for docetaxel, 21 (87%) received it. Grade
3/4 toxicities were neutropenia (39%), febrile neutropenia (14%),
esophagitis (14%), and pneumonitis (4%). Median survival was 34
months, and 1-year survival was 66%. Survival was not significantly
different in squamous and other histology patients. Tumor analysis
in 16 patients showed that moderate/strong expression of thymidy-
late synthase was significantly associated with progression-free
survival and overall survival.
Conclusion: Integrating pemetrexed in a concurrent therapy regi-
men for patients with stage III NSCLC is feasible and was associ-
ated with a median survival of 34 months.
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Approximately, 33% of patients with non-small cell lungcancer (NSCLC) have stage III disease at diagnosis. The
accepted therapy for patients with unresectable stage III
NSCLC is concurrent chemotherapy and chest radiotherapy
(CRT).1,2 This standard reflects the understanding that both
local tumor and systemic micrometastases need to be treated.
Nevertheless, it is challenging to combine some of the newer
chemotherapy agents at full dose with CRT.3–5 Therefore, the
combination of cisplatin and etoposide is commonly used for
the management of patients with stage III NSCLC because
these agents can be combined with CRT at full doses. The
Southwest Oncology Group (SWOG) developed a regimen of
concurrent cisplatin/etoposide and CRT followed by do-
cetaxel. In a phase II study, S9504, this regimen resulted in a
median survival of 27 months.6 Nevertheless, both local and
distant control rates were suboptimal in this trial. Therefore,
there is a need to explore alternative regimens.
Pemetrexed is a multitargeted antifolate, with thymidy-
late synthase (TS) as one of the primary targets. It was
initially approved for the treatment of recurrent NSCLC7,8
and subsequently received approval for front line and main-
tenance therapy for patients with advanced nonsquamous
NSCLC.9,10 Seiwert et al.11 conducted a phase I study eval-
uating pemetrexed and carboplatin with CRT and found that
it was feasible to combine pemetrexed/carboplatin at full dose
with CRT.
On the basis of these results, we initiated a phase II
study evaluating pemetrexed and cisplatin with CRT for the
management of patients with stage III NSCLC. On the basis
of S9504, we planned consolidation docetaxel after concur-
rent therapy.
METHODS
Eligibility
Eligibility criteria included stage IIIA or IIIB NSCLC
(without malignant pleural effusion) according to the Amer-
*Thoracic Oncology Program, Karmanos Cancer Institute/Wayne State Uni-
versity; †John D. Dingell VA Medical Center; and ‡Translational Re-
search Core Laboratory, Karmanos Cancer Institute, Detroit, Michigan.
Disclosure: Dr. Shirish M. Gadgeel and Dr. Antoinette Wozniak have
received honorarium and consultant fees from Eli Lilly.
Address for correspondence: Shirish M. Gadgeel, MD, 4100 John R, 4
HWCRC, Detroit, MI. E-mail: gadgeels@karmanos.org
John C. Ruckdeschel is currently at Nevada Cancer Institute, Las Vegas, NV.
Andrew Turrisi is currently at Detroit Medical Center, Detroit, MI.
Presented at the 44th Annual Meeting of American Society of Clinical
Oncology held in June 2008 in Chicago, Illinois.
Registered at clinicaltrials.gov—identifier number—NCT00301808.
Copyright © 2011 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/11/0605-0927
Journal of Thoracic Oncology • Volume 6, Number 5, May 2011 927
ican Joint Committee on Cancer Staging (AJCC) and Union
Internationale Contre le Cancer (UICC) sixth edition12 per-
formance status 0 to 1, forced expiratory volume in 1 second
(FEV1) of 1 liter or more and pulmonary diffusion capacity
of at least 50% of predicted, and adequate hematologic,
hepatic, and renal functions. Patients had to have calculated
total lung volume receiving 20 Gy (V20) 40%. The study
was approved by the institutional review boards of Karmanos
Cancer Institute and John D. Dingell VA Medical Center. All
patients were required to provide signed informed consent.
Treatment
Patients received three cycles of cisplatin and pem-
etrexed 500 mg/m2 on days 1, 22, and 43. The first five
patients received cisplatin 60 mg/m2 per cycle. The dose of
cisplatin was escalated to 75 mg/m2 per cycle for all the
subsequent patients. Patients received vitamin B12, folic
acid, dexamethasone, and antiemetics as indicated. On the
day of each cycle, patients received hydration as considered
necessary for cisplatin therapy. Treating physicians were
encouraged to administer 1 liter of normal saline the day after
each cycle of chemotherapy.
Patients received CRT starting within 24 hours of the
first dose of chemotherapy. The initial field received 2 Gy/d
for 5 weeks for a dose of 50 Gy. An additional radiation boost
to the gross tumor volume was administered with 2 Gy/d for
16 Gy, for a total tumor dose of 66 Gy. Both computed
tomography (CT) scans and positron emission tomography
(PET)/CT scans established the target volume. The gross
tumor volume was defined as the tumor, the ipsilateral hilum,
and nodes positive on PET or mediastinal staging procedures,
or nodes 1 cm short axis on CT scan. The clinical target
volume included 2 to 3 mm radially and adjusted for motion
as imaged on conventional simulators. Treatment planning
was done, such that at no point along the spinal cord the
radiation dose exceeded 50 Gy.
Patients without evidence of disease progression and
patients who had recovered from the adverse effects of
concurrent therapy were treated with three cycles of do-
cetaxel at 75 mg/m2 every 21 days, starting no earlier than 4
weeks after completion of concurrent therapy. All patients
received either pegylated filgrastim or filgrastim after each
cycle of docetaxel.
Treatment Modifications
This study used the National Cancer Institute Common
Toxicity Criteria version 3.0 for adverse event reporting. A
delay in starting second and third cycles of pemetrexed/
cisplatin for a maximum of 2 weeks was allowed for recovery
from any adverse effects. Doses of both were reduced by 20%
for grade 4 hematologic toxicity or any nonhematologic
toxicity that was grade 3 in the prior cycle. A break in
radiotherapy was allowed, but was not mandated, for severe
esophagitis and/or grade 4 hematologic toxicity. A delay in
starting second and third cycles of docetaxel for a maximum
of 2 weeks was allowed for recovery of any adverse effects.
Patients with grade 3/4 adverse events were required to have
appropriate dose modifications for the next cycle.
Study Evaluation and Follow-Up
All patients had disease assessment with appropriate
scans after completion of concurrent therapy and within 4
weeks after completing docetaxel. All surviving patients were
required to undergo disease assessment at 1 year. PET/CT
scans were required after completion of concurrent therapy
and 1 month after completion of docetaxel. Patients enrolled
at the VA medical center were excluded from follow-up PET
scans.
Thymidylate Synthase and Excision Repair
Cross Complementation Group 1 Expression
Immunohistochemistry analysis was performed using
archival blocks from consenting patients by standard meth-
odology.13 In brief, 4 to 5 m paraffin sections on frosted
slides (Snowcoat X-tra, Surigpath, Richmond, IL) were de-
waxed and rehydrated through a xylene-ethanol series, and
endogenous peroxides were removed by incubation of the
slides in 1.2% hydrogen peroxide in methanol. Antigen re-
trieval was done in citrate buffer pH 6.0 in the microwave.
Slides were blocked with 10% goat serum in phosphate-
buffered saline (PBS) for 1 hour and incubated with the
primary antibodies over night at 4°C. The mouse monoclonal
Excision Repair Cross Complementation Group 1 (ERCC1)
antibody used was from Neomarkers (Freemont, CA; Ab-2,
clone 8F1dilution 1:200) and the mouse monoclonal TS
antibody used was from Abcam (Cambridge, MA; clone TS
106, dilution 1:50). Normal mouse immunoglobulins (St.
Cruz Biotechnol., St. Cruz, CA) were used instead of primary
antibodies to probe negative control sections. Slides were
then washed with PBS for three times and probed with the
SuperPicture horse raddish peroxidase conjugate secondary
antibody (Invitrogen, Camarillo, CA) for 2 hours, washed
with PBS, and developed with diaminobenzidine substrate
(Invitrogen). The tissues were counterstained with Gill’s
hematoxylin solution (Fisher Scientific, Pittsburgh, PA), de-
hydrated, and coverslipped with Eukitt mounting solution
(Sigma, St Louis, MO).
Protein expression and staining intensity were evalu-
ated in a blinded fashion by two independent observers
(A.M.B. and L.M.). Nuclear expression of ERCC1 and TS
were evaluated using a semiquantitative scoring system of 0
to 3 as reported by us earlier14 (0  no expression, 0.5 to
1  weak expression, 1.5 to 2.5  moderate expression,
and 3  strong expression). Three independent experi-
ments were performed and a mean generated of the resulting
six scores by the two observers.
Statistical Methods
The primary objective of this study was to estimate the
1-year survival rate. Secondary endpoints were response rate,
progression-free survival (PFS), and toxicity assessment. We
hypothesized that the1-year survival proportion is 0.55 for
such patients from our cancer center’s referral population,
based on 1999–2001 survival statistics from the Detroit
Surveillance Epidemiology End Results registry. We wish to
find sample evidence from the study that supported the
conclusion that the true 1-year survival proportion is not less
than 0.45. As this was among the first trials evaluating the
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incorporation of pemetrexed in a regimen of concurrent therapy
for a patient population that has potentially curable disease, our
primary concern was to be certain that this regimen did not
increase the potential of inferior survival. A sample size of 28
produces a one-sided 85% lower-limit Wilson’s confidence
interval with the lower bound greater than 0.45. A statistical
monitoring plan for toxicity, especially aimed at the occurrence
of grades 3 to 4 radiation esophagitis and grades 3 to 4 radiation
pneumonitis was also instituted.
Point and exact confidence interval estimates of the
toxicity and response rates were computed. All time-to-event
distribution functions were estimated using standard Kaplan-
Meier (KM) methods for censored data, from which the
median and other statistics of interest were calculated.
For the biomarker analysis, the baseline enzyme ex-
pression levels (ERCC1 and TS) were dichotomized into high
(moderate/strong expression) and low levels. The association
between the time-to-event outcomes and enzyme levels was
explored using KM curves stratified by each enzyme level
and explored using Cox model adjusted for histology type.
The proportional hazard assumptions were checked using the
time-dependent variable models.
All the statistical tests are traditional two sided at  
0.05. Given the nature of this exploratory study, p values are
not adjusted for multiple testing.
RESULTS
Patient Characteristics
Twenty-eight patients were enrolled from May 2006 to
March 2009 (Table 1). The median age was 60 years, 64%
had stage IIIB NSCLC, 68% were men, 54% were current
smokers, and 43% had squamous cell histology. The median
FEV1 was 2.26 liters (mean 2.31 liters), and the median V20
was 29%; seven patients (25%) had V20 more than 35%.
Treatment Delivery
Of the 28 patients who started on therapy, 24 patients
(86%) completed all three cycles of cisplatin/pemetrexed.
Among the five patients who started cisplatin at 60 mg/m2, all
completed the planned three cycles. Among the 23 patients
who started cisplatin at 75 mg/m2, 19 (83%) completed all
three cycles of therapy at full dose and on schedule. Reasons
for not completing all cycles of therapy were death (one),
progressive disease (one), and toxicities (two; esophagitis and
fatigue). Twenty-seven patients completed CRT and received
the total planned dose. Five (19%) patients had delays in the
radiation therapy, two due to esophagitis, one due to hemop-
tysis resulting in hospital admission, one due to dehydration,
and one due to noncompliance.
Of the 24 patients (three progressed and one died before
docetaxel) eligible for docetaxel therapy, 21 patients (88%)
went on to receive docetaxel, and 18 patients (86%) com-
pleted all three cycles of docetaxel therapy and did so at full
dose. Decline in performance status was the reason for three
patients not receiving docetaxel. Sixteen patients (57%) com-
pleted all components of therapy.
Toxicity
Two patients died while on therapy or soon after. One
patient died of severe hematemesis of unclear etiology 1
month after completing concurrent therapy but before the
patient could get docetaxel, and the other patient developed a
cerebrovascular accident after the first cycle of therapy. Both
deaths were considered not to be related to the study treat-
ment. During concurrent therapy, grades 3 to 4 neutropenia
occurred in 11 patients (39%), and four patients (14%)
developed febrile neutropenia (Table 2). Grade 3/4 esophagi-
tis was observed in four (14%) patients and pneumonitis in
one (4%) patient. During concurrent therapy, three patients
developed grade 3 renal failure; two patients developed renal
failure when admitted for infections and received antibiotics that
can be nephrotoxic. All patients recovered their renal function to
baseline. Grade 2 fatigue was a common adverse event ob-
served in 20 patients during concurrent therapy and among 14
patients during docetaxel therapy. Fourteen patients developed
symptoms of grade 2 esophagitis during docetaxel. During
concurrent therapy and docetaxel therapy, grade 1 diarrhea
TABLE 1. Patient Demographics
Demographic
Variable All Patients Part II Patientsa
Number 28 21
Age (yr)
Median 60 62
Sex
Female 9 (32%) 7 (33%)
Male 19 (68%) 14 (66%)
Race
White 20 (71%) 15 (71%)
African American 7 (25%) 5 (24%)
Asian 1 (4%) 1 (5%)
Stage
IIIA 10 (36%) 9 (43%)
IIIB 18 (64%) 12 (57%)
Performance status
0 7 (25%) 5 (24%)
1 21 (75%) 16 (76%)
Histology
Squamous 12 (43%) 9 (43%)
Adenocarcinoma 15 (54%) 11 (52%)
Large cell 1 (3%) 1 (5%)
Smoking history
Never 1 (3%) 1 (5%)
Current 15 (54%) 12 (57%)
Former 12 (43%) 8 (38%)
FEV1
Median (range) 2.26 liter (1.07–3.43) 2.19 liter (1.07–3.43)
DLCO
Median (range) 67% (50–100%) 63% (50–92%)
V20
Median (range) 29% (7–39.6%) 30.6% (7–39.6%)
a Patients who received consolidation docetaxel after concurrent therapy.
FEV1, forced expiratory volume in 1 second; DLCO, pulmonary diffusion capacity;
V20, total lung volume receiving 20 Gy.
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occurred in six and two patients, respectively; grade 2 stomatitis
occurred in one patient each; and grade 1 neuropathy occurred in
one patient each. Late toxicities attributable to the therapy have
not been observed to date.
Efficacy
The median follow-up for all patients is 41 months
(Table 3). The median overall survival (OS) was 34 months
and 1-year survival rate was 66% using KM estimate (Figure
1). The median PFS was 16 months, and 1-year PFS rate was
55%. The response rate was 64%. As pemetrexed may not be
efficacious in patients with squamous cell carcinoma, we
analyzed the outcomes separately in these patients (Figure 2).
The median follow-up for squamous cell patients is 29
months, and the median follow-up for nonsquamous patients
cell is 41 months. The median PFS in squamous cellpatients
and nonsquamous patients were 19 and 13 months, respec-
tively, and the 1-year PFS rate was 57% and 52%, respec-
tively. The median survival of squamous cell patients was 25
months and 36 months in nonsquamous patients. We ana-
lyzed the correlation of the following factors: age, sex,
histology, smoking status, FEV1 and pulmonary diffusion
capacity to survival, and PFS and found none to be signifi-
cantly associated with OS or PFS (data not shown).
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FIGURE 1. Overall survival of all enrolled patients.
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FIGURE 2. Survival of squamous cell patients and nonsqua-
mous cell patients.
TABLE 2. Grade 3/4 Toxicities During Concurrent Therapy
(Part I) and during Docetaxel Therapy (Part II)
Part I,
N  28 (%)
Part II,
N  21 (%)
Hematologic toxicities
WBC 12 (43) 0
Neutrophils 11 (39) 0
Febrile neutropenia 4 (14) 0
Nonhematologic toxicities
Esophagitis 4 (14) 0
Pneumonitis 1 (4) 0
Hemoglobin 3 (11) 0
Vomiting 1 (4) 0
Hyperglycemia 3 (11) 5 (25)
Hypoglycemia 0 1 (5)
Infection 0 1 (5)
Renal failure 3 (11) 0
Hyponatremia 1 (4) 0
Hyperkalemia 1 (4) 0
Othera 0 1 (5)
a Patient developed grade 3 hemoptysis.
WBC, white blood cell.
TABLE 3. Survival Outcome: Progression-Free Survival (PFS)
and Overall Survival (OS)
N Events
Point
Estimate
95%
Confidence
Interval
PFS 28 20
Median 16.4 mo 6.7 mo 35.7 mo
1 yr rate 55% 37% 74%
By histology
Squamousa 12 8
Median 18.7 mo 2.3 mo 45.9 mo
1 yr rate 57% 29% 85%
Nonsquamousa 16 12
Median 13.2 mo 4.2 mo 34.6 mo
1 yr rate 52% 27% 76%
OS 28 14
Median 33.8 mo 8.0 mo b
1 yr rate 66% 48% 84%
By histology
Squamousa 12 6
Median 25.2 mo 0.0 mo b
1 yr rate 66% 38% 94%
Nonsquamousa 16 8
Median 35.9 mo 9.3 mo b
1 yr rate 64% 41% 88%
a The differences in either PFS or OS between squamous cell patients and patients
with nonsquamous histologies were not statistically significant.
b These values cannot be calculated (either due to the censoring pattern or else the
value is not reached).
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Sites of First Failure
Eighteen patients have developed progression. Four
patients (22%) developed brain metastases only as the first
site of progression. Five patients (28%) developed distant
metastases, other than brain metastases, as the first site of
progression, and five patients (28%) developed local progres-
sion as the first site of progression. Four patients developed
both local and distant progression.
Tumor ERCC1 and TS Expression
The decision to analyze these markers was taken after
the study started (Tables 4 and 5). Therefore, only 18 patients
could be consented for this assessment, and of these 18
patients, adequate tumor for analysis was available in only 16
patients (nine adenocarcinomas and seven squamous cell
carcinomas). The hazard ratios for both survival and PFS
were higher for moderate or strong ERCC1 and TS expres-
sion, but only the TS expression was significantly associated
with both PFS and OS.
DISCUSSION
This is among the first trials to evaluate the combina-
tion of cisplatin and pemetrexed administered concurrently
with CRT in patients with stage III NSCLC. These results
show that it is feasible to combine pemetrexed and cisplatin
at full doses with 66 Gy CRT. The 1-year survival of 66% is
similar to other regimens, and the median survival of 34
months is very promising.
Despite the acceptance of concurrent therapy as the
standard treatment for patients with stage III NSCLC, there is
no consensus on the specific chemotherapy regimen. In the
United States, the two commonly used regimens are cisplatin/
etoposide and weekly carboplatin with paclitaxel. The me-
dian survival in phase III trials, with the current regimens, is
21 months.5 Based on the results of a phase I trial con-
ducted by Seiwert et al.6,11 and the results of S9504, we
planned the current trial of cisplatin and pemetrexed with
CRT followed by three cycles of docetaxel. This treatment
plan, therefore, included three of the most active agents for
the treatment of NSCLC, with different putative mechanisms
of action, providing the possibility of improved local and
distant control.
Before the start of this trial, there were no data avail-
able regarding the feasibility of combining cisplatin with
pemetrexed and CRT. We, therefore, treated the first five
patients with a dose of 60 mg/m2/cycle of cisplatin (total
dose, 180 mg/m2), a dose comparable with the total cisplatin
dose of 200 mg/m2 used in S9504. As these five patients
tolerated the concurrent therapy well, we decided to escalate
the cisplatin dose to 75 mg/m2/cycle because this is the dose
used when cisplatin is combined with pemetrexed in ad-
vanced NSCLC and malignant mesothelioma.9,15
The treatment delivery rates in this trial are similar to
S9504. Twenty-four (86%) patients completed all three cy-
cles of cisplatin/pemetrexed when compared with 88% of the
patients in S9504 completing cisplatin/etoposide. Twenty-
one patients (75%) went on to receive docetaxel in this trial
and 78% in S9504. The febrile neutropenia rate of 14% in this
trial is slightly higher than other concurrent therapy regi-
mens.6,8,16 Nevertheless, the rate of severe neutropenia at
39% was not excessive. The rates of grade 3/4 esophagitis
and pneumonitis, two major adverse events observed with
concurrent therapy in patients with NSCLC, were comparable
with the rates observed in other trials.
The Cancer and Leukemia Group B (CALGB) recently
presented the results of CALGB 30407, a study evaluating
the combination of carboplatin area under the curve 5, pem-
etrexed 500 mg/m2, and CRT 70 Gy.17 Patients were also
randomized to receive cetuximab or not. After completion of
concurrent therapy, patients were to receive four additional
cycles of pemetrexed. Of the 99 eligible patients, 85% of the
patients completed concurrent therapy. The median survival
was 22 months. The incidence of severe neutropenia (50%),
febrile neutropenia (7%), esophagitis (28%), and pneumonitis
(10%) in the CALGB 30407 trial were similar to the rates
observed in the current trial.
Other studies have evaluated the integration of pem-
etrexed in concurrent treatment strategies for locally ad-
vanced NSCLC and found the strategy to be feasible. Brade
et al.18 recently reported results of 39 patients enrolled on a
phase II study evaluating the combination of pemetrexed at
500 mg/m2 on day 1 and cisplatin 20 mg/m2 on days 1 to 5
every 21 days for two cycles with radiation therapy of 61 to
66 Gy over 6 to 6.5 weeks. After completion of concurrent
TABLE 4. Expression of ERCC1 and Thymidylate Synthase
Biomarker
Histology
Total
(N  16)
Squamous
(N  7)
Adenocarcinoma
(N  9)
ERCC1
No expression 1 4 5
Weak expression 2 3 5
Moderate expression 3 2 5
Strong expression 1 0 1
TS
No expression 1 3 4
Weak expression 2 3 5
Moderate expression 1 3 4
Strong expression 3 0 3
TABLE 5. Hazard Ratio (Adjusted for Histology) for
Moderate or Strong Expression of ERCC1 and TS
Biomarker Hazard Ratio 95% CI p
Survival
ERCC1 2.25 0.47–10.76 0.311
TS 16.65 2.06–134.94 0.0084
PFS
ERCC1 1.56 0.41–5.89 0.513
TS 8.87 1.76–44.64 0.0081
Patient numbers, 16; moderate or Strong Expression ERCC, 1 to 6/16; moderate or
Strong TS, 7/16.
CI, confidence interval; ERCC1, Excision Repair Cross Complementation Group 1;
TS, thymidylate synthase; PFS, progression-free survival.
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therapy, patients were scheduled to receive two more cycles
of pemetrexed and cisplatin (75 mg/m2) every 21 days.
Seventy-four percent of patients (29/39) completed all
planned four cycles of chemotherapy, which is a higher rate
than the rate of 57% observed in this study. The major
hematologic toxicity was neutropenia (10 patients), and non-
hematologic toxicites were nausea/emesis (n  4), fatigue/
syncope (n  4),and esophagitis (n  2). Grade 3/4 pneu-
monitis was observed in only one patient. The 1-year OS and
PFS rates were 80% and 47%, respectively. Similarly, Choy
et al.19 reported the results of an ongoing study randomizing
patients with stage III NSCLC to pemetrexed with carbopla-
tin (area under the curve 5) or pemetrexed with cisplatin (75
mg/m2) administered every 3 weeks for three cycles with
radiation therapy of 64 to 68 Gy. Among 71 patients, the
combination was well tolerated. The response rates in the
carboplatin (15 patients evaluable) and cisplatin (20 patients
evaluable) arms were 47% and 60%, respectively. Ma et al.
presented their results on 21 patients who underwent two
cycles of carboplatin and pemetrexed with 62 Gy radiation
therapy followed by three more cycles of carboplatin and
pemetrexed. They reported an impressive response rate of
86% and found that the outcomes in patients with adenocar-
cinoma were better.20 Mornex et al.21 recently reported on a
phase I study evaluating the strategy of induction therapy
with two cycles of pemetrexed and cisplatin followed by
pemetrexed with cisplatin and radiation therapy. The inves-
tigators found this strategy to be feasible. The main toxicities
were cytopenias and nausea and emesis. One patient did
develop septic shock. The results from these studies suggest
that integration of pemetrexed/platinum combination with
radiation therapy for the treatment of stage III NSCLC is
feasible. The data regarding toxicity and efficacy in this study
are similar to the results reported by other investigators.
The median survival in many phase II trials for stage III
NSCLC is in the range of 25 months.16,22,23 The results of the
current trial may be influenced by the stringent eligibility
criteria of the study. All the patients in the current trial
underwent PET scans, something that was not done routinely
in the previous phase II and phase III trials. PET scans permit
selection of patients likely to have better outcomes.24–26 In
addition, the eligibility criteria mandated that the V20 should
be 40%. Previous studies have shown that V20 values can
correlate with radiotherapy-related toxicities.27,28 Southwest
Oncology Group presented data showing that patients with
V20 more than 35% have inferior survival.29 Thus, these
eligibility criteria, not routinely included in prior studies, may
have selected for patients that were likely to have a better
outcome.
The benefit of consolidation docetaxel in the current
regimen is unclear. We included docetaxel in this regimen
because it was the accepted standard at the time this study
was initiated. Hoosier Oncology Group LUN 01-24/USO-023
was designed to test the utility of consolidation docetaxel.30
Growth factors after docetaxel were not mandated, and the
eligibility criteria regarding PFTs were less stringent in the
HOG trial. The results of this study showed that consolidation
docetaxel did not improve survival and increased toxicities.
Consolidation docetaxel was well tolerated in the current trial
and was not associated with severe toxicities or mortality. It
is unclear, if consolidation docetaxel administered with
growth factors in patients with adequate PFTs could provide
survival advantage. Nevertheless, extending chemotherapy
beyond concurrent therapy can be challenging as suggested
by less than 60% of the patients completing all planned
therapy in the current trial and in CALGB30407.17 Therefore,
the need for docetaxel in this regimen is unclear.
During the trial, it became known that histology is an
important predictor of pemetrexed efficacy.9,10 In this study,
there was no difference in efficacy of the regimen based on
histologic categories; however, the number of patients were
small to be certain of differential efficacy of this regimen in
different histologic subtypes. In CALGB30407 as well, there
was no significant difference in efficacy between squamous
and other histologies. Nevertheless, Ma et al.20 reported that
they found better outcomes in patients with adenocarcinoma
with the combination of carboplatin/pemetrexed with radia-
tion therapy. Whether concurrent therapy regimens that in-
clude pemetrexed will have differential effects according to
histology, as observed in advanced stage NSCLC, will only
be clear once the results of all the studies evaluating this
strategy are available.
It has been suggested that the lack of efficacy of
pemetrexed in squamous cell patients is related to higher TS
expression.31 We analyzed TS and also ERCC1, a possible
marker of efficacy for platinum compounds,32 by immuno-
histochemistry and found a trend for increased hazard ratio
for survival and PFS in patients with tumors that had mod-
erate/strong expression of TS and ERCC1. The hazard ratios
for ERCC1 were lower than the hazard ratios for TS, and the
association of TS with both survival and PFS was statistically
significant. The results of TS and ERCC1 expression in the
current trial have to be considered hypothesis generating as
the analysis was unplanned and conducted only in 16 pa-
tients. The observation that TS expression may have greater
association with clinical outcomes in patients treated with this
regimen than ERCC1 needs to be assessed in future studies.
The major limitation of this study is the small number
of patients. Also the enrollment is only from two sites. When
the study was planned, there were no data of combining
cisplatin with pemetrexed with radiation therapy, and the
amount of data on the use of pemetrexed in patients with
NSCLC was limited. We, therefore, designed the study to
ensure that the outcome with this regimen was not inferior to
the outcomes observed with existing regimens in this poten-
tially curable patient population. The statistical design re-
quired enrollment of 28 patients to assess this objective.
In conclusion, the current trial has shown that cisplatin/
pemetrexed at full dose with CRT in patients with stage III
NSCLC is feasible, and the outcomes of these patients are
comparable with current regimens. These results need to be
confirmed in larger trials. Currently, there is a phase III trial
evaluating the combination of pemetrexed with cisplatin and
CRT in patients with nonsquamous NSCLC.33 The results of
this phase III trial will further define the value of integrating
Gadgeel et al. Journal of Thoracic Oncology • Volume 6, Number 5, May 2011
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pemetrexed in concurrent therapy for patients with stage III
NSCLC.
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